VG Life Sciences (VGLS) 10-Q 13 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 15, 2014
Document And Entity Information	'	'
Entity Registrant Name	'VG Life Sciences Inc.	'
Entity Central Index Key	'0001091326	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	31,815,628
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2014	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
CURRENT ASSETS	'	'
Cash	$53,842	$713,892
Prepaid expenses and other current assets	6,621	75,494
Total Current Assets	60,463	789,386
PROPERTY AND EQUIPMENT, NET	0	0
OTHER ASSETS	'	'
Intangible assets	1,076,836	1,076,836
TOTAL ASSETS	1,137,299	1,866,222
CURRENT LIABILITIES	'	'
Accounts payable	866,146	405,000
Accrued expenses	182,730	434,471
Accrued interest	265,001	69,898
Insurance finance agreement	0	33,836
Convertible debt - related parties	2,599,689	1,844,732
Convertible debt - other	1,098,360	1,363,272
Derivative liabilities	1,295,487	2,183,440
Total Current Liabilities	6,307,413	6,334,649
COMMITMENTS AND CONTINGENCIES	'	'
STOCKHOLDERS' DEFICIT	'	'
Preferred stock, 20,000,000 shares authorized, $0.0001 par value; 9,715,443 and 9,715,443 issued and outstanding, respectively	972	972
Common stock, 150,000,000 shares authorized, $0.0001 par value; 31,230,318 and 17,459,752 issued and outstanding, respectively	3,123	1,746
Additional paid-in capital	99,696,993	94,609,247
Noncontrolling interests	673,115	698,921
Deficit accumulated during the development stage	-105,544,317	-99,779,313
Total Stockholders' Deficit	-5,170,114	-4,468,427
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$1,137,299	$1,866,222

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares issued	9,715,443	9,715,443
Preferred stock, shares outstanding	9,715,443	9,715,443
Common stock, shares authorized	150,000,000	150,000,000
Common stock, par value	$0.00	$0.00
Common stock, shares issued	31,230,318	17,459,752
Common stock, shares outstanding	31,230,318	17,459,752

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended		231 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014
Income Statement [Abstract]	'	'	'	'	'
REVENUES	$0	$0	$0	$0	$347,750
EXPENSES	'	'	'	'	'
Research and development	339,881	300,196	975,864	349,636	18,964,648
Management salaries	214,376	259,425	780,625	489,307	6,657,399
Depreciation and amortization	0	0	0	0	1,645,748
Legal and professional	179,878	190,723	1,077,551	696,586	8,402,688
Consulting fees	0	50,415	37,629	152,915	19,561,051
General and administrative	64,637	52,873	730,502	84,649	10,439,268
Total expenses	798,772	853,632	3,602,171	1,773,093	65,670,802
LOSS FROM OPERATIONS	-798,772	-853,632	-3,602,171	-1,773,093	-65,323,052
OTHER INCOME (EXPENSE)	'	'	'	'	'
Asset impairment	0	0	0	0	-475,000
Sale of distribution rights	0	0	0	0	1,309,966
Interest income	0	0	0	0	9,392
Derivative benefit/(expense)	414,895	-633,000	-94,935	-2,098,134	-5,043,766
Interest expense	-687,800	-71,672	-2,093,704	-502,875	-36,269,992
Total other income (expense)	-272,905	-704,672	-2,188,639	-2,601,009	-40,469,400
NET LOSS	-1,071,677	-1,558,304	-5,790,810	-4,374,102	-105,792,452
NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTERESTS	8,602	9,297	25,806	31,703	248,135
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	($1,063,075)	($1,549,007)	($5,765,004)	($4,342,399)	($105,544,317)
NET LOSS PER COMMON SHARE, BASIC AND DILUTED	($0.04)	($0.18)	($0.24)	($0.68)	'
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED	28,935,882	8,403,425	23,986,056	6,354,005	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended		231 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014
Cash Flows From Operating Activities:	'	'	'
Net loss attributable to controlling interests	($5,765,004)	($4,342,399)	($105,544,317)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation	0	0	1,645,748
Amortization of debt discount	1,878,116	74,472	9,265,943
Debt Issuance costs	0	0	13,339,211
Imputed Interest	0	63,300	189,826
Non-Controlling Interest	-25,806	-31,703	-248,135
Services included in accounts payable to be satisfied in shares	0	0	200,000
Issuance of common stock and warrants for services	54,756	0	677,006
Stock based compensation	0	0	1,890,449
Issuance of common stock for services and finders fee	0	0	7,864,423
Issuance of convertible notes for services	1,001,565	627,277	2,495,575
Beneficial conversion feature	0	0	71,500
Issuance of preferred stock for interest	0	0	225,000
Settlement-distribution agreement rights	0	0	1,668,953
Debt Settlement liabilities and common shares in excess of recorded liabilities	0	0	399,530
Issuance of stock and warrants for interest and financing costs	0	0	7,730,776
Non-cash operating expenses and other charges	0	0	5,387,663
Non-cash income-gain on settlements	0	0	-384,966
Options and warrants issued for services and wages	597,269	347,600	13,243,795
Options exercised for services	0	0	116,317
Contingently issued stock issued for services	0	0	792,499
Warrants exercised for services	0	0	12,500
Issuance of common stock for expenses paid by third party	0	0	593,947
Issuance of common stock for settlement agreement	0	0	1,060,000
Notes payable issued for expenses	0	0	897,306
Notes payable converted to accrued wages	0	0	-25,000
Satisfaction of Syexia-in excess of accrual	0	0	104,577
Change in variable common stock purchase options	0	0	-22,418
(Increase) decrease in prepaid expenses and other current assets	68,873	0	-97,941
(Increase) decrease in deposits and other assets	0	0	1,972,832
Increase (decrease) in accrued interest	195,102	49,103	1,486,762
Increase (decrease) in accounts payable	461,144	199,838	1,778,853
Increase (decrease) in accrued expenses	-62,997	416,206	2,594,291
Increase (decrease) in accrued wages payable	0	0	771,744
Increase (decrease) in advances-related parties	0	0	74,283
Increase (decrease) in advances	0	0	136,000
Increase (decrease) in insurance finance agreement	0	0	33,836
Increase (decrease) in convertible debt-related parties and other	0	0	-112,475
Increase (decrease) in derivative liability	94,935	2,098,134	4,802,935
Net cash used in operating activities	-1,502,047	-498,172	-22,911,172
Cash Flows From Investing Activities:	'	'	'
Increase in leasehold improvements	0	0	-1,039,306
Acquisition of equipment	0	0	-361,665
Increase in intangible assets	0	0	-5,206,051
Net cash used in investing activities	0	0	-6,607,022
Cash Flows From Financing Activates:	'	'	'
Proceeds of MedBridge Debt	0	0	125,000
Proceeds from convertible debt-related party and other	875,833	628,002	7,482,433
Payment for convertible debt-related party and other	-33,836	-121,038	-930,603
Proceeds from sale of common stock and warrants, net	0	0	11,082,204
Proceeds from Revolving line of credit-related party	0	0	3,087,432
Repayments of Revolving line of credit-related party	0	0	-1,694,162
Proceeds of sale of VGE securities to third parties, net	0	0	600,000
Proceeds from notes payable	0	0	267,000
Proceeds from exercise of options and warrants	0	0	173,061
Proceeds from notes payable--related parties	0	0	9,379,671
Net cash provided by financing activities	841,997	506,964	29,572,036
Increase (decrease) in Cash	-660,050	8,792	53,842
Cash and cash equivalents, beginning of period	713,892	6,090	0
Cash and cash equivalents, end of period	53,842	14,882	53,842
SUPPLEMENT DISCLOSURE OF CASH FLOW INFORMATION Cash paid during the period for:	'	'	'
Interest	0	0	0
Income taxes	0	0	0
NON-CASH TRANSACTIONS	'	'	'
Issuance of common stock and warrants for convertible notes and interest	0	0	6,072,377
Discount on indebtedness	1,807,205	330,472	10,472,155
Reclassification of derivative liability to additional paid-in-capital	0	0	1,264,800
Conversion of various accruals to convertible notes	0	0	1,953,954
Issuance of common stock in satisfaction of accounts payable/notes/accruals	1,645,439	532,500	5,432,742
Refinancing of convertible debt -related party Revolving line of credit	0	0	3,180,393
Issuance of common shares in various debt settlements and partial satisfactions	0	0	629,451
Issuance of unsecured convertible debentures for accounts payable	0	0	476,866
Issuance of common stock for debt repayment-DMBM/Wonderland, net	0	0	35,214
Noncontrolling interest, net	0	0	2,447
Issuance of common stock for T & T legal and accrued interest	0	0	1,035,000
Issuance of convertible note to acquire interest in unconsolidated subsidiary	0	0	782,814
Issuance of common shares, options and warrants- V Clip acquisition	0	0	1,502,479
Issuance of common shares - repurchase product royalty rights, China Market	0	0	231,000
Issuance of common shares and warrants - Carcinotek acquisition	0	0	1,000,000
Restructuring of convertible debentures	0	0	1,198,167
Issuance (settlement) of unsecured convertible debentures - patents	0	0	248,000
Issuance of common stock for debt paid by third party	0	0	593,947
Issuance of common stock for debt and interest	0	0	9,086,511
Issuance of common stock finders fee	0	0	450,000
Warrants issued with convertible debentures and amendment of arrangement	0	0	516,800
Transfer from derivative liabilities	984,455	798,048	2,988,878
Issuance of warrant in partial consideration of notes payable	0	0	100,000
Issuance of note in consideration of White Label acquisitions	0	0	100,000
Issue Series A Preferred Stock for secured revolving credit note	$0	$0	$252,000

1_Organization_and_Description

1. Organization and Description of Business	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
1. Organization and Description of Business	'
	VG Life Sciences Inc. (the “Company” or “VGLS”) was incorporated in California on July 11, 1995 and is in the development stage. The Company is engaged in research and development of therapeutic and diagnostic pharmaceutical and medical products. The Company was acquired by a publicly traded Delaware Corporation and became a reporting issuer on October 1, 2001. On November 5, 2001, this publicly traded company changed its name to Viral Genetics, Inc. On November 26, 2012, the Company’s name was changed to VG Life Sciences Inc. from Viral Genetics, Inc. The Company terminated registration with the SEC on March 24, 2009. The Company became a reporting issuer again on August 22, 2014. The Company’s fiscal year-end is December 31.
	As of September 30, 2014, the Company has the following subsidiaries:
		Origination/	Ownership
	Subsidiary Name	Acquisition Date	Percentage
	V-Clip Pharmaceuticals	2008	100%
	Carcinotek, Inc.	2008	100%
	White Label Generics, Inc.	2008	49%
	MetaCytolytics, Inc.	2009	100%
	Viral Genetics Beijing, Ltd.	2009	100%
	VG Energy, Inc. (“VGE”)	2010	81.65%
	The various subsidiaries were organized or acquired to facilitate the use of the Company’s Targeted Peptide Technology (“TPT”) and Metabolic Disruption Technology (“MDT”). As of September 30, 2014 and December 31, 2013, all subsidiaries were inactive.

2_Basis_of_Presentation

2. Basis of Presentation	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
2. Basis of Presentation	'
	The accompanying unaudited interim consolidated financial statements as of September 30, 2014 and for the three and nine month periods ended September 30, 2014 and 2013 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and on the same basis as the audited annual consolidated financial statements. The unaudited interim consolidated balance sheet as of September 30, 2014, unaudited interim consolidated statements of operations for the three and nine month periods ended September 30, 2014 and 2013, and the unaudited interim consolidated statements of cash flows for the nine month periods ended September 30, 2014 and 2013 include all material adjustments, consisting only of normal recurring adjustments (unless otherwise discussed below), which management considered necessary for a fair presentation of the financial position and operating results for the periods presented. These unaudited financial statements are the representations of management. The results for the three and nine month periods ended September 30, 2014 are not necessarily indicative of results to be expected for the year ending December 31, 2014 or for any future interim period. The audited consolidated balance sheet at December 31, 2013 has been derived from the audited consolidated financial statements; however, the notes to the accompanying unaudited consolidated financial statements do not include all of the information and notes required by accounting principles generally accepted in the United States of America for complete consolidated financial statements. The accompanying unaudited consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2013 included in Amendment # 2 of the Company’s Form 10 filed with the Securities and Exchange Commission on October 1, 2014. These accompanying notes are generally limited to the information necessary to update the information included in the aforementioned financial statements for the year ended December 31, 2013.
	Going Concern
	As of September 30, 2014, the Company had a deficit accumulated during the development stage of approximately $105.5 million and requires substantial additional funds to continue its research and development, to support its operations and to achieve its business development goals, the attainment of which are not assured. The Company has been able to satisfy certain liabilities with convertible indebtedness and common shares and enter into debt settlement arrangements, facilitated by third party financing, with vendors and creditors for substantial amounts of its various financial obligations. Convertible instruments have also been converted into equity. In September 2013, the Company also entered into arrangements with related parties under which it has and will continue to receive certain financial and administrative support and services through March 18, 2015 and has consummated related party and unrelated convertible debenture and warrant agreements from which it will receive cash and executive services (from related parties only). However, substantial indebtedness remains and substantial recurring losses from operations and additional liabilities continue to be incurred.
	These factors and uncertainties raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might incur in the event the Company cannot continue in existence. Management has designed plans for sales of the Company’s future pharmaceutical related products. Management intends to seek additional capital from new equity securities offerings, from debt financing and debt restructuring to provide funds needed to increase liquidity, fund internal growth and fully implement its business plan. However, management can give no assurance that these funds will be available in adequate amounts, or if available, on terms that would be satisfactory to the Company.
	The timing and amount of the Company’s capital requirements will depend on a number of factors, including the need for funds to support research and development and payment requirements to sustain licensing rights, demand for products and services and the availability of opportunities for international expansion through affiliations, to maintain its status as a public company, shareholder and investor relations, to establish and maintain current and new business relationships and for other general corporate business purposes.

3_Convertible_Debt_Other

3. Convertible Debt - Other	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
3. Convertible Debt - Other	'
	On January 24, 2014, KED Consulting Group LLC, (“KED”) entered into a Convertible Promissory Note and Warrant Purchase Agreement with the Company in the amount of $270,000. The notes are unsecured, bear interest at 8% per annum, and are convertible into common shares at $0.0588 per share. KED also received warrants to purchase 1,080,000 shares at $0.45 per share on execution of this agreement, exercisable at any time from the four year anniversary to the fifth year anniversary of this arrangement. Shares will be issuable on conversion of these notes in total in four equal tranches (25% each) on the following dates: December 15, 2014, March 15, 2015, June 15, 2015 and September 15, 2015, to the extent not earlier converted, at the conversion price per share ($0.0588). All proceeds were received by September 30, 2014. Of the $270,000: $100,000 was to be paid directly in satisfaction of a vendor liability of ours, which has been paid, and $170,000 was to be paid in cash in six equal monthly payments of $28,333. The final payment was received on September 30, 2014. Debt discount of $270,000 was recorded of which $58,704 and $130,508 was amortized as interest expense in the three and nine month periods ended September 30, 2014, respectively.
	Effective March 1, 2014, investors in unsecured convertible debentures aggregating a total of $165,000 exchanged these debentures and any associated warrants (waiving any defaults and accrued interest on the notes) for an equal principal amount under a Convertible Promissory Notes and Warrants Purchase Agreement with the same terms and conditions as described in the preceding paragraph. These investors received warrants to purchase an aggregate of 660,000 common shares, with the same terms and conditions as described preceding paragraph. Debt discount of $165,000 was recorded of which $70,620 and $92,740 was amortized as interest expense in the three and nine month periods ended September 30, 2014, respectively.
	Effective August 27, 2014, the Company received proceeds of $50,000 from an unrelated investor, pursuant to a Convertible Promissory Note and Warrant Purchase Agreement under terms and conditions that are the same as those described in Note 4, except that this note is due on August 22, 2016 and this investor has the right to purchase notes totaling $150,000 through August 21, 2015. Principal and accrued interest are convertible in four equal quarterly tranches of principal, plus accrued interest commencing on November 22, 2015, or at any time at the investor’s option, at the conversion price. Debt discount of $50,000 was recorded of which $3,064 was amortized as interest expense in the nine month period ended September 30, 2014.

4_Convertible_Debt_Related_Par

4. Convertible Debt - Related Parties	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
4. Convertible Debt - Related Parties	'
	In the nine month period ended September 30, 2014, the Company entered into Convertible Promissory Notes (“Notes”) and Warrant Purchase Agreements with three related party entities: on July 9, 2014 with Wild Harp Holdings, LLC (“Wild Harp”) controlled by John Tynan, our CEO, and DW Odell Company (“DW Odell”) controlled by David Odell, our CFO, and on August 27, 2014, with Medbridge Development Company, LLC (“MDC”), an entity controlled by Mr. Tynan and Mr. Odell. John Tynan and David Odell are officers and directors of the Company. The Wild Harp and DW Odell agreements provide for Notes of up to $250,000 each to be purchased at the option of each party through July 9, 2015, of which $150,000 has been received from each of Wild Harp and DW Odell through September 30, 2014. The MDC agreement provides for a Note of $50,000, proceeds of which were received from MDC on August 27, 2014. All three Notes bear interest at 8% per annum and have a two year term. Principal and accrued interest are convertible in four equal quarterly tranches of principal, plus accrued interest commencing 15 months after the issuance date of each Note, or at any time at each party’s option, at the conversion price. The Wild Harp and DW Odell balances are each comprised of two Notes having identical conversion provisions; (i) a Note with $100,000 in principal with a conversion rate of $0.1245 and warrant exercise price of $0.93 per share and (ii) a Note with $50,000 in principal with a conversion rate of $0.084 and warrant exercise price of $0.63 per share. The MDC Note of $50,000 has a conversion price of $0.1134 and a warrant exercise price of $0.85 per share. The warrants received by the parties are to purchase four common shares for each $1 of principal, an aggregate of 1,400,000 shares as of September 30, 2014, exercisable on any date from the four-year anniversary to the five-year anniversary of the agreement. Similar warrants will be issued with future Wild Harp and DW Odell note proceeds of up to $200,000, if any; exercisable at 7.5 times the corresponding conversion price. All warrants include a cashless exercise provision. These Notes issued through September 30, 2014, are convertible into 3,237,819 shares of common stock of the Company.

5_Equity_Incentive_Plan

5. Equity Incentive Plan	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
5. Equity Incentive Plan	'
	In the three and nine month periods ended September 30, 2014, the Company granted 1,515,000, and 4,545,000, respectively, non-qualified stock options under its 2013 Equity Incentive Plan to management and consultants. The fair value of these options was estimated using the Black-Scholes Option Pricing Model with the following assumptions: risk free annual interest ranging from 2.52% to 2.73%; volatility approximating 127%; expected life of 5 years; and no expected dividends. The aggregate fair value of these options granted for the nine months ended September 30, 2014 of $597,269 was included in research and development in the amount of $59,136 and general and administrative expense in the amount of $538,133.

6_Common_and_Preferred_Stock

6. Common and Preferred Stock	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
6. Common and Preferred Stock	'
	Effective on July 9, 2014, the Company filed a certificate of amendment to its Delaware Certificate of Incorporation increasing the total number of authorized shares of capital stock to 170,000,000 from 160,000,000. The total number of authorized Preferred Shares was increased to 20,000,000 from 10,000,000 and authorized Common Shares remained at 150,000,000; each having a par value of $0.0001 per share. Also on July 9, 2014, the Company established a Series B Preferred Stock ("Series B"), which the Company removed through an Amendment and Restatement of the Articles of Incorporation on September 4, 2014 and an Amended and Restated Certificate of Designation on September 4, 2014.

7_Subsequent_Events

7. Subsequent Events	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
7. Subsequent Events	'
	On March 28, 2014, the Company entered into an Investment Agreement (“the Agreement”) with Dutchess Opportunity Fund II L.P. (“Dutchess”) whereby Dutchess may purchase up to that number of common shares having an aggregate purchase price of $5,000,000. Under terms of the Agreement, the Company may, at its sole discretion, deliver a Put Notice to Dutchess stating the dollar amount of common shares, which the Company intends to sell to Dutchess on a closing date. The maximum amount that Dutchess can be required to purchase at any one time shall be equal to (1) 200% of the average daily volume for the three trading days immediately preceding the formal date of the notice to Dutchess or (2) $150,000, determined at the sole discretion of the Company. The share purchase price is 94% of the lowest daily volume-weighted average price of Company stock for the 5 consecutive trading days beginning with the notice date and the ensuing four trading days. The Agreement is for a term of three years from the date of execution, or, if earlier, the sale of $5,000,000 or written notice to Dutchess by the Company. On September 4, 2014, the Company and Dutchess amended the agreement to require the Company to file a Registration Statement on Form S-1 (or other appropriate form) with the SEC covering any registrable securities that may be issued under the Investment Agreement within 30 days of the completion of the review of the Form 10 by the SEC. The Company was notified by the SEC of the completion of the SEC’s review on October 14, 2014. The Company must initially register for resale up to 10,000,000 shares of common stock, except to the extent that the SEC requires the share amount to be reduced as a condition of effectiveness.
	On October 27, 2014, the Company received an additional $100,000 in proceeds from Wild Harp and DW Odell pursuant to the arrangements described in Note 4.

1_Organization_and_Description1

1. Organization and Description of Business (Tables)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Subsidiary information	'
		Origination/	Ownership
	Subsidiary Name	Acquisition Date	Percentage
	V-Clip Pharmaceuticals	2008	100%
	Carcinotek, Inc.	2008	100%
	White Label Generics, Inc.	2008	49%
	MetaCytolytics, Inc.	2009	100%
	Viral Genetics Beijing, Ltd.	2009	100%
	VG Energy, Inc. (“VGE”)	2010	81.65%

1_Organization_and_Description2

1. Organization and Description of Business (Details - Subsidiary listing)	9 Months Ended
	Sep. 30, 2014
V-Clip Pharmaceuticals [Member]	'
Acquisition date	'2008
Ownership percentage	100.00%
Carcinotek, Inc. [Member]	'
Acquisition date	'2008
Ownership percentage	100.00%
White Label Generics, Inc. [Member]	'
Acquisition date	'2008
Ownership percentage	49.00%
MetaCytolytics, Inc. [Member]	'
Acquisition date	'2009
Ownership percentage	100.00%
Viral Genetics Beijing, Ltd. [Member]	'
Acquisition date	'2009
Ownership percentage	100.00%
VG Energy, Inc. (VGE) [Member]	'
Acquisition date	'2010
Ownership percentage	81.65%

2_Basis_of_Presentation_Detail

2. Basis of Presentation (Details Narrative) (USD $)	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Deficit accumulated during development stage	($105,544,317)

3_Convertible_Debt_Other_Detai

3. Convertible Debt - Other (Details Narrative) (USD $)	9 Months Ended		231 Months Ended	3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
				Convertible Debt [Member]	Convertible Debt [Member]	Convertible Debt [Member]	Convertible Debt [Member]	Convertible Debt [Member]
				KED [Member]	KED [Member]	Unsecured Debt [Member]	Unsecured Debt [Member]	Unrelated investor [Member]
Debt face amount	'	'	'	$270,000	$270,000	$165,000	$165,000	'
Interest rate	'	'	'	8.00%	8.00%	8.00%	8.00%	'
Conversion price per share	'	'	'	$0.06	$0.06	$0.06	$0.06	'
Debt discount	'	'	'	270,000	270,000	165,000	165,000	50,000
Debt discount amortized as interest expense	'	'	'	58,704	130,508	70,620	92,740	3,064
Warrants issued with note payable	'	'	'	'	1,080,000	'	660,000	'
Proceeds from convertible promissory note	$875,833	$628,002	$7,482,433	'	'	'	'	$50,000

4_Convertible_Debt_Related_Par1

4. Convertible Debt - Related Parties (Details Narrative) (USD $)	9 Months Ended		231 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014
Proceeds from convertible promissory notes	$875,833	$628,002	$7,482,433
Convertible Debt [Member] | Conversion of Stock	'	'	'
Notes convertible into shares of common stock	3,237,819	'	'
Convertible Debt [Member] | Wild Harp Holdings LLC [Member]	'	'	'
Proceeds from convertible promissory notes	150,000	'	'
Interest rate	8.00%	'	8.00%
Note description	'Principal and accrued interest are convertible in four equal quarterly tranches of principal, plus accrued interest commencing 15 months after the issuance date of each Note, or at any time at each partyBs option, at the conversion price. The Wild Harp and DW Odell balances are each comprised of two Notes having identical conversion provisions; (i) a Note with $100,000 in principal with a conversion rate of $0.1245 and warrant exercise price of $0.93 per share and (ii) a Note with $50,000 in principal with a conversion rate of $0.084 and warrant exercise price of $0.63 per share.	'	'
Convertible Debt [Member] | DW Odell [Member]	'	'	'
Proceeds from convertible promissory notes	150,000	'	'
Interest rate	8.00%	'	8.00%
Note description	'Principal and accrued interest are convertible in four equal quarterly tranches of principal, plus accrued interest commencing 15 months after the issuance date of each Note, or at any time at each partyBs option, at the conversion price. The Wild Harp and DW Odell balances are each comprised of two Notes having identical conversion provisions; (i) a Note with $100,000 in principal with a conversion rate of $0.1245 and warrant exercise price of $0.93 per share and (ii) a Note with $50,000 in principal with a conversion rate of $0.084 and warrant exercise price of $0.63 per share.	'	'
Convertible Debt [Member] | MDC [Member]	'	'	'
Proceeds from convertible promissory notes	$50,000	'	'
Interest rate	8.00%	'	8.00%
Note description	'The MDC Note of $50,000 has a conversion price of $0.1134 and a warrant exercise price of $0.85 per share.	'	'

5_Equity_Incentive_Plan_Detail

5. Equity Incentive Plan (Details Narrative) (Stock Options [Member], USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014
Stock options granted	1,515,000	4,545,000
Assumptions used	'	'
Risk free interest rate, minimum	2.52%	'
Risk free interest rate, maximum	2.73%	'
Volatility rate	127.00%	'
Expected life	'5 years	'
Expected dividends	$0	'
Fair value of options granted	'	597,269
Research and Development Expense [Member]	'	'
Assumptions used	'	'
Fair value of options granted	'	59,136
General and Administrative Expense [Member]	'	'
Assumptions used	'	'
Fair value of options granted	'	$538,133